Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046411 | 0.89 | TSHR (0.47) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL9668058 | 0.87 | TSHR (0.52) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| Dimethyl Succinate SCHEMBL11848625 | 0.86 | TSHR (0.81) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL7421083 | 0.85 | TSHR (0.64) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL280333 | 0.85 | TSHR (0.71) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| Triethylene Glycol SCHEMBL17687575 | 0.84 | TSHR (0.48) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL22310268 | 0.83 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2ATET2 | |
| Dimethyl Succinate SCHEMBL28054469 | 0.83 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| Dimethyl Succinate SCHEMBL10213 | 0.83 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL3007115 | 0.81 | TSHR (0.56) | TSHRLMNAKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796922-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SELENO AMINO ACID COMPOUND FOR USE IN COMBINATION WITH ANOTHER AGENT FOR THE TREATMENT OF LIVER OR PANCREAS CANCER | SELEQ OY (FI) | 2026-03-18 | — | — | EP | claimed |
| CN-120078761-A | Application of alpha-ketoglutarate in preparation of antihypertensive angiogenesis promoting medicine | 中山大学附属第一医院 | 2025-06-03 | — | — | CN | claimed |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | SELEQ OY (FI) | 2025-05-27 | — | — | US | claimed |
| US-20250136932-A1 | COMPOSITIONS AND METHODS FOR CULTURING AND MAINTAINING TROPHOBLAST STEM CELLS | NORTH CAROLINA STATE UNIVERSITY | 2025-05-01 | — | — | US | claimed |
| CN-119799846-A | Method for detecting ALKBH enzyme activity of plant and application | 湖北大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119587524-A | Application of alpha ketoglutarate prodrug in preparation of medicines for treating myelodysplastic syndrome | 浙江大学 | 2025-03-11 | — | — | CN | claimed |
| US-20240279593-A1 | METHOD OF PRODUCING BIOLOGICAL MATERIAL | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2024-08-22 | — | — | US | claimed |
| US-20240263128-A1 | METHOD OF PRODUCING BIOLOGICAL MATERIAL | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2024-08-08 | — | — | US | claimed |
| EP-4408980-A2 | LINEAGE SPECIFICATION DURING STEM CELL TRANSITION | Amniotics AB (SE) | 2024-08-07 | — | — | EP | claimed |
| CN-118105371-A | Application of alpha-ketoglutarate dimethyl ester in preparation of medicine for treating ischemic myocardial infarction dead heart function insufficiency syndrome | 广州中医药大学第一附属医院 | 2024-05-31 | — | — | CN | claimed |
| US-20170333373-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-23 | — | — | US | claimed |
| EP-3218010-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | Spirea Limited (GB) | 2017-09-20 | — | — | EP | claimed |
| US-20170224828-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | SPIREA LIMITED (GB) | 2017-08-10 | — | — | US | claimed |
| US-20170175164-A1 | L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-06-22 | — | — | US | claimed |
| EP-3122893-A1 | L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM | Memorial Sloan Kettering Cancer Center (US) | 2017-02-01 | — | — | EP | claimed |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2016-09-01 | — | — | US | claimed |
| EP-3052133-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2016059391-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | OUBERAI MYRIAM MARIE (GB) | 2016-04-21 | — | — | WO | claimed |
| WO-2015148950-A1 | L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-10-01 | — | — | WO | claimed |
| WO-2015049365-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224828-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | IL1R1, SRRM2, H1-2 | TSHR 372/4885LMNA 684/4885KDM4E 3616/4885 |
| US-20170333373-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | GCDH, OGDH, GLS | TSHR 4562/4885LMNA 2974/4885KDM4E 1712/4885 |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | BECN1, ATG7, SQSTM1 | TSHR 4684/4885LMNA 981/4885KDM4E 4030/4885 |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | RNASE1, SELENOI, GLS2 | TSHR 2063/4885LMNA 4033/4885KDM4E 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.